Skip to main content

Advertisement

Fig. 5 | Cell Communication and Signaling

Fig. 5

From: Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin

Fig. 5

TCTP partially protects HCT116 colon cancer cells against toxicity induced by 5-FU or oxaliplatin. a Effect of TCTP knock-down on cellular sensitivity to 5-FU or oxaliplatin, assessed by the the xCELLigence RTCA System. HCT116 cells were either mock-transfected or transfected with TCTP siRNA or Luciferase siRNA (as a control) using Lipofectamine™ RNAiMAX transfection reagent for 24 h, and subsequently incubated in the presence of the indicated concentrations of either 5-FU or oxaliplatin. Cell growth was monitored in real-time using the xCELLigence RTCA System. Representative growth curves are shown in the left panels for control cells and for treatment with 12.5 μM 5-FU or oxaliplatin, as an example. Relative cell numbers are expressed as Cell Index (CI). Right panels compare the relative CI-values for Luc-siRNA, and TCTP-siRNA at the time point, when the control cells reached a CI value of 10 (5-FU treatment) or of 5 (oxaliplatin treatment). b Effect of TCTP knock-down on cellular sensitivity to 5-FU or oxaliplatin, measured by the MTS endpoint assay for cytotoxicity. TCTP-siRNA or GAPDH-siRNA (as a control) were transfected into HCT116 cells using Lipofectamine™ RNAiMAX transfection reagent and, after 24 h, incubated in the presence of the indicated concentrations of drugs for another 48 h. Cell viability was assessed using the MTS endpoint assay and was plotted against the concentration of 5-FU (left graph) and that of oxaliplatin (right graph). Statistical significance was ascertained using 2WAY ANOVA (****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05)

Back to article page